NYSEARCA:PTN - NYSE Arca - US6960775020 - Common Stock - Currency: USD
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024.
Palatin Technologies (PTN) stock plunged 40% Wednesday after the company said a Phase 3 pivotal study for its drug PL9643 failed to meet a co-primary endpoint. Read more here.
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
Palatin (PTN) announces a registered direct offering of approximately 1.83 million shares at $5.46 per share, alongside a concurrent private placement of...
These penny stocks have triple-digit upside as 2024 brings easing monetary policy and economic normalization.
These high-risk, high-reward bets could be at an inflection point before their growth takes off next year.
It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today!
Read about Palatin Technologies (PTN) filing a prospectus for the offer and sale of 2,476,416 shares of common stock by selling stockholders.
Palatin Technologies (PTN) announces a direct offering of 2.358M common shares at $2.12 per share, along with warrants and a closing date of October 24,...
Palatin Technologies said Thursday its preliminary gross product revenue for Vyleesi was $4.6 million for the first quarter of fiscal 2024. Read more.
/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...
Palatin Technologies receives notice of non-compliance from NYSE American due to inadequate stockholders' equity, but no immediate impact on stock trading.